Response to sorafenib treatment in advanced metastatic thyroid cancer
| Autor: | Fabián Pitoia |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Compassionate Use Trials
Male Niacinamide Sorafenib medicine.medical_specialty Lung Neoplasms Endocrinology Diabetes and Metabolism medicine.medical_treatment Antineoplastic Agents Bone Neoplasms Thyroglobulin Gastroenterology Metastasis thyroid Iodine Radioisotopes Stable Disease Internal medicine Metastático medicine cancer Humans Thyroid Neoplasms Adverse effect Response Evaluation Criteria in Solid Tumors Aged Heart Failure câncer business.industry Phenylurea Compounds Thyroid sorafenibe General Medicine Middle Aged medicine.disease Carcinoma Papillary Surgery Treatment Outcome medicine.anatomical_structure Heart failure Toxicity sorafenib Female business Progressive disease tireoide Follow-Up Studies medicine.drug |
| Zdroj: | Arquivos Brasileiros de Endocrinologia & Metabologia v.58 n.1 2014 Arquivos Brasileiros de Endocrinologia & Metabologia Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) instacron:SBEM Arquivos Brasileiros de Endocrinologia & Metabologia, Volume: 58, Issue: 1, Pages: 37-41, Published: FEB 2014 |
| ISSN: | 0004-2730 |
| DOI: | 10.1590/0004-2730000002839 |
| Popis: | Objective: To investigate the efficacy of sorafenib in progressive radioiodine resistant metastatic thyroid carcinoma.Subjects and methods: Off-label observational study. Sorafenib 400 mg twice daily was evaluated. Therapy duration was 12 ± 3 months (range 6-16 months).Results: Eight patients were included (seven papillary, one insular variant). The eight patients meeting study criteria received sorafenib 400 mg orally twice a day until disease progression or unacceptable toxicity developed. One patient showed a partial response with tumor regression of -35%, six months after the beginning of the treatment; five patients exhibited stable disease and two patients had progressive disease and died. Thyroglobulin decreased within 4 weeks in all patients by 50% ± 23%.Adverse events: one patient had heart failure, and recovered after sorafenib withdrawal. However, she died five months later of sudden death.Conclusion: These data suggest a possible role for sorafenib in the treatment of progressive metastatic DTC. Adverse event are usually manageable, but severe ones may appear and these patients should be strictly controlled. Objetivo: Investigar a eficácia do sorafenibe no carcinoma de tireoide metastático progressivo e refratário à iodoterapia.Sujeitos e métodos: Estudo observacional do efeito do sorafenibe off-label administrado 400 mg duas vezes ao dia. A duração da terapia foi de 12 ± 3 meses (variação de 6-16 meses).Resultados: Oito pacientes foram incluídos (sete com variante papilífera e um com variante insular). Os oito pacientes que preencheram os critérios do estudo receberam o sorafenibe 400 mg por via oral duas vezes por dia até progressão da doença ou toxicidade inaceitável. Um paciente apresentou uma resposta parcial com regressão tumoral da lesão alvo de 35% seis meses após o início do tratamento; cinco pacientes apresentaram doença estável e dois pacientes progrediram e morreram. A tireoglobulina diminuiu 50% ± 23% em 4 semanas em todos os pacientes.Eventos adversos: um paciente teve insuficiência cardíaca e morreu por morte súbita cinco meses após a retirada do sorafenibe.Conclusão: Esses dados sugerem um possível papel para sorafenibe para o tratamento do CDT metastático progressivo. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|